Novo Nordisk CEO: Pills could capture 50% of obesity drug market by 2030

Novo Nordisk's CEO projects oral obesity treatments could take up to half the global market by 2030, as the company pivots from injectables. Novo has five oral candidates in development and already launched the first obesity pill, beating Eli Lilly. The claim is a corporate forecast, not a market fact, and hinges on pipeline success and competitor response.